secwatch.observer — SEC 8-K summary
======================================

Issuer:     NutriBand Inc. (NTRB)
CIK:        0001676047
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001213900-25-102930
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nutriband receives FDA feedback on AVERSA FENTANYL CMC plans; regulatory pathway confirmed as 505(b)(2)
--------------------------------------------------------------------------------

- FDA meeting held September 18, 2025; final minutes received; feedback on CMC, registration batch, and stability plans.
- FDA confirmed 505(b)(2) NDA path and provided guidance on reference drug bridging strategy.
- Company plans to file IND to support a Human Abuse Potential clinical study for the abuse-deterrent fentanyl patch.
- Partner Kindeva to develop AVERSA FENTANYL combining Nutriband's AVERSA technology with Kindeva's FDA-approved fentanyl patch.
- Peak annual US sales potential estimated at $80M to $200M per market analysis report.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676047/000121390025102930/0001213900-25-102930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676047/000121390025102930/ea0262795-8k_nutriband.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-102930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer